- Home
- RDIB vs QTTB Comparison
RDIB vs QTTB Comparison
Compare RDIB & QTTB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | RDIB | QTTB |
|---|---|---|
| Founded | 1937 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Movies/Entertainment | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 263.5M | 450.1M |
| IPO Year | 1994 | 2018 |
Fundamental Metrics
Financial Performance| Metric | RDIB | QTTB |
|---|---|---|
| Price | $11.21 | $8.65 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $39.67 |
| AVG Volume (30 Days) | 8.2K | ★ 795.0K |
| Earning Date | 11-13-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 60.76 | ★ 136.78 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $202,988,000.00 | $53,737,000.00 |
| Revenue This Year | $15.10 | N/A |
| Revenue Next Year | $4.04 | $150.00 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $8.00 | $1.91 |
| 52 Week High | $24.00 | $23.57 |
Technical Indicators
Market Signals| Indicator | RDIB | QTTB |
|---|---|---|
| Relative Strength Index (RSI) | 38.70 | 43.78 |
| Support Level | $10.28 | $7.45 |
| Resistance Level | $12.59 | $9.16 |
| Average True Range (ATR) | 0.62 | 0.55 |
| MACD | -0.32 | 0.27 |
| Stochastic Oscillator | 3.78 | 71.73 |
Price Performance
Historical ComparisonAbout RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.
About QTTB Q32 Bio Inc.
Q32 Bio Inc is a clinical-stage biotechnology company focused on developing novel biologics to restore healthy immune balance in patients with alopecia areata (AA) and other autoimmune and inflammatory diseases driven by immune dysfunction. Its product candidate, bempikibart (ADX 914), is a fully human anti-interleukin 7 receptor alpha (IL-7R) antagonist monoclonal antibody designed to block signaling mediated by interleukin 7 (IL 7) and thymic stromal lymphopoietin (TSLP) and re-regulate adaptive immune function. The company has completed two Phase 2a clinical trials evaluating bempikibart, SIGNAL AA Part A for the treatment of alopecia areata and SIGNAL AD for the treatment of atopic dermatitis (AD).